Eli Lilly Sues over US Sales of Tirzepatide for Weight Loss

Posted By Madilyn Moeller, Thursday, September 21, 2023

Scale and measuring tape

Eli Lilly on Tuesday said it was suing 10 U.S. medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, the active ingredient in its diabetes drug Mounjaro which is expected to be approved for weight loss later this year.

In four separate lawsuits filed in Florida and Texas federal courts, Eli Lilly is seeking orders barring Better Life Pharmacy, ReviveRX, Rx Compound Store and Wells Pharmacy Network from selling tirzepatide, and requesting unspecified damages.

The Indianapolis-based drugmaker is accusing the four compounding pharmacies, which make customized drug preparations for customers, of violating federal and state consumer protection and competition laws by selling unregulated versions of Mounjaro.

Lilly is the only company with U.S. Food and Drug Administration approval to sell tirzepatide drugs.

The drugmaker is seeking similar injunctive orders and damages against six medical spas and wellness centers from federal courts in Arizona, Florida, Georgia, Minnesota, South Carolina and Utah, accusing them of infringing its trademark by advertising compounded tirzepatide as Mounjaro.

Read more at Reuters >>

Discover more about compounding pharmacies and this summer’s lawsuits from the maker of Ozempic and Wegovy when you visit AmSpa’s Medical Aesthetic Semaglutide Resource Center at https://americanmedspa.org/med-spa-semaglutides.